Major increase of quetiapine steady-state plasma concentration following co-administration of clarithromycin: confirmation of the pharmacokinetic interaction potential of quetiapine.
Schulz-Du Bois
C
C
Schulz-Du Bois
A C
AC
Bewig
B
B
Gerstner
I
I
Aldenhoff
J B
JB
Cascorbi
I
I
Ufer
M
M
D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000097:blood* / Q000493:pharmacokinetics / Q000506:poisoning; D017291:Clarithromycin / Q000009:adverse effects* / Q000627:therapeutic use; D003987:Dibenzothiazepines / Q000097:blood* / Q000493:pharmacokinetics / Q000506:poisoning; D004347:Drug Interactions; D062787:Drug Overdose; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications / Q000188:drug therapy; D011618:Psychotic Disorders / Q000150:complications / Q000188:drug therapy; D000069348:Quetiapine Fumarate
D000900:Anti-Bacterial Agents; D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate; D017291:Clarithromycin